Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24763601 | 0.88 | KMT2A (0.43) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL8441895 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL23252489 | 0.84 | KMT2A (0.50) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL8327967 | 0.83 | HSD11B1 (0.41) | SMN1; SMN2KMT2AKDM4EALDH1A1HRH3 | |
| SCHEMBL11891622 | 0.82 | KMT2A (0.50) | KMT2AMEN1RAB9ANOS3NOS1 | |
| SCHEMBL13456545 | 0.82 | KDM4E (0.35) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL12104157 | 0.82 | DRD3 (0.44) | KMT2AMEN1RAB9A | |
| SCHEMBL12464449 | 0.79 | NOS3 (0.44) | SMN1; SMN2KDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL19000002 | 0.79 | PIK3CD (0.38) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL1307796 | 0.79 | ALOX15 (0.46) | KMT2AMEN1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018089695-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-8097630-B2 | Pinane-substituted pyrimidinediamine derivatives derivatives and pharmaceutical compositions containing the dthe activity of the receptor protein tyrosine kinase Axl. Methods of using erivatives are disclosed as being useful in inhibiting activity of enzyme | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885KMT2A 1063/4885MEN1 4517/4885 |
| US-20110269737-A1 | 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases | MAPKAPK2, MAPKAPK5, MAPK7 | SMN1; SMN2 4332/4885KMT2A 1609/4885MEN1 4674/4885 |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | CHKA, CHKB, CEPT1 | SMN1; SMN2 2555/4885KMT2A 1408/4885MEN1 1547/4885 |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SMN1; SMN2 2889/4885KMT2A 2123/4885MEN1 945/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | SMN1; SMN2 4050/4885KMT2A 1145/4885MEN1 4487/4885 |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | SMN1; SMN2 882/4885KMT2A 1137/4885MEN1 385/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | SMN1; SMN2 3475/4885KMT2A 833/4885MEN1 4472/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 2610/4885KMT2A 1153/4885MEN1 4690/4885 |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | SMN1; SMN2 3487/4885KMT2A 3115/4885MEN1 4367/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | SMN1; SMN2 4772/4885KMT2A 3524/4885MEN1 2417/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | SMN1; SMN2 4772/4885KMT2A 3524/4885MEN1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.